Zhuo Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhuo Chen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Wenzi Zhang
School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China
4 shared publicationsXiaoming Sun
School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China
4 shared publicationsXinyu Wang
School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China
3 shared publicationsChanglong Gou
Taihe Hospital, Hubei University of Medicine, Shiyan, China
2 shared publicationsDanni Wang
School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China
2 shared publicationsXianhui Wang
Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China; Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan 442000, China
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Oligonucleotide G3T19 downregulates CD44 succinylation and inhibits astrocyte-induced glioma immune escape
Astrocytes (ACs) play a crucial role within the immune microenvironment of glioma, facilitating its progression. Protein succinylation, a post-translationa
- 21 July 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessOligonucleotide G3T19 downregulates CD44 succinylation and inhibits astrocyte-induced glioma immune escape
Astrocytes (ACs) play a crucial role within the immune microenvironment of glioma, facilitating its progression. Protein succinylation, a post-translationa
- 31 March 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 154, 114548
The dual effects of propofol down-regulating PD-L1 expression and inhibiting autophagy to reduce cerebral ischemia reperfusion injury
- 31 March 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 154, 114548
The dual effects of propofol down-regulating PD-L1 expression and inhibiting autophagy to reduce cerebral ischemia reperfusion injury
- Top Cited PapersOpen Access
- 18 March 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-15
An examination of the LPS-TLR4 immune response through the analysis of molecular structures and protein–protein interactions
The LPS-TLR4 immune response is a critical mechanism in the body's defense against Gram-negative bacterial infections, yet its dysregulation can lead to severe inflammatory diseases. Lipopolysaccharide (LPS), a pivotal pathogen-associated molecular pattern (PAMP) on the surface of gram-negative bacteria, is recognized by Toll-like receptor 4 (TLR4), initiating a complex cascade of immune responses. This review delves into the intricate molecular structures and protein–protein interactions that underpin the LPS-TLR4 signaling pathway, offering a comprehensive analysis of both extracellular recognition and intracellular signal transduction. We explore the roles of key molecules such as LBP, CD14, MD-2, and TLR4 in the initial recognition of LPS, followed by the downstream signaling pathways mediated by MyD88-dependent and MyD88-independent mechanisms. The MyD88-dependent pathway primarily activates NF-κB and AP-1, leading to macrophage M1 polarization and the release of pro-inflammatory cytokines, while the MyD88-independent pathway triggers IRF activation and type-I interferon production. By elucidating the structural basis and functional interactions of these signaling molecules, this review not only enhances our understanding of the LPS-TLR4 immune response but also highlights its implications in both infectious and non-infectious diseases. Our findings underscore the potential of targeting this pathway for therapeutic interventions, offering new avenues for the treatment of inflammatory and immune-related disorders.
- 18 March 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-15
Top Cited PapersOpen AccessAn examination of the LPS-TLR4 immune response through the analysis of molecular structures and protein–protein interactions
The LPS-TLR4 immune response is a critical mechanism in the body's defense against Gram-negative bacterial infections, yet its dysregulation can lead to severe inflammatory diseases. Lipopolysaccharide (LPS), a pivotal pathogen-associated molecular pattern (PAMP) on the surface of gram-negative bacteria, is recognized by Toll-like receptor 4 (TLR4), initiating a complex cascade of immune responses. This review delves into the intricate molecular structures and protein–protein interactions that underpin the LPS-TLR4 signaling pathway, offering a comprehensive analysis of both extracellular recognition and intracellular signal transduction. We explore the roles of key molecules such as LBP, CD14, MD-2, and TLR4 in the initial recognition of LPS, followed by the downstream signaling pathways mediated by MyD88-dependent and MyD88-independent mechanisms. The MyD88-dependent pathway primarily activates NF-κB and AP-1, leading to macrophage M1 polarization and the release of pro-inflammatory cytokines, while the MyD88-independent pathway triggers IRF activation and type-I interferon production. By elucidating the structural basis and functional interactions of these signaling molecules, this review not only enhances our understanding of the LPS-TLR4 immune response but also highlights its implications in both infectious and non-infectious diseases. Our findings underscore the potential of targeting this pathway for therapeutic interventions, offering new avenues for the treatment of inflammatory and immune-related disorders.
- Open Access
- 6 September 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 983537
INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway
INPP4B (Inositol polyphosphate 4-phosphatase type II) has been regarded as a suppressor of several human tumors, but its biological function, expression, and clinical significance in glioma tissues and cell lines are unclear. Notably, whether INPP4B participates in immune escape of glioma deserves urgent attention. Here, we confirmed that INPP4B expression is often downregulated in low- and high-grade human glioma tissues, in tissues from an orthotopic mouse model of brain glioma and in glioma cells. We found that INPP4B overexpression restrained the proliferation, migration, apoptosis resistance, PD-L1 expression, and T cell suppression by glioma cells, whereas INPP4B silencing had the opposite effects. Moreover, we showed that INPP4B inhibited glioma cell proliferation, migration, and PD-L1 expression by downregulating PI3K/AKT signaling. Collectively, these data support that INPP4B may inhibit glioma progression, and particularly, glioma’s immune escape. Thus, INPP4B may constitute a valuable target for glioma treatment.
- 6 September 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 983537
Open AccessINPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway
INPP4B (Inositol polyphosphate 4-phosphatase type II) has been regarded as a suppressor of several human tumors, but its biological function, expression, and clinical significance in glioma tissues and cell lines are unclear. Notably, whether INPP4B participates in immune escape of glioma deserves urgent attention. Here, we confirmed that INPP4B expression is often downregulated in low- and high-grade human glioma tissues, in tissues from an orthotopic mouse model of brain glioma and in glioma cells. We found that INPP4B overexpression restrained the proliferation, migration, apoptosis resistance, PD-L1 expression, and T cell suppression by glioma cells, whereas INPP4B silencing had the opposite effects. Moreover, we showed that INPP4B inhibited glioma cell proliferation, migration, and PD-L1 expression by downregulating PI3K/AKT signaling. Collectively, these data support that INPP4B may inhibit glioma progression, and particularly, glioma’s immune escape. Thus, INPP4B may constitute a valuable target for glioma treatment.